阿里健康(0241.HK)跳水跌超7% 2020財年營收增速放緩、毛利率下滑
格隆匯5月28日丨早盤高開2.43%的阿里健康(0241.HK)開盤後逐步走低,目前更是出現一波跳水走勢,跌7.3%報16.76港元,暫成交5.5億港元,最新總市值2180億港元。公司昨晚公佈截至2020年3月31日的年度業績顯示,營收95.96億元,同比增長88.3%;年度淨虧損為1569.6萬元,上年同期淨虧損9176.4萬元,虧損幅度收窄82.9%。但值得注意的是,公司2017財年至2019財年的營收增速均為三位數,相比之下,公司2020財年營收增速有所放緩。另外,阿里健康在報告期內的毛利率有所下滑,其2020財年毛利率為23.3%,2019財年毛利率為26.1%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.